{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:46:47Z","timestamp":1760204807173},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T00:00:00Z","timestamp":1434326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.semarthrit.2015.06.003","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T23:06:28Z","timestamp":1434582388000},"page":"163-166","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"45","author":[{"given":"Dominic","family":"Borie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2015.06.003_bib1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/652438","article-title":"Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988\u20132004","volume":"50","author":"Bate","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein\u2013Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/597126","article-title":"Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors","volume":"199","author":"Egli","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib4","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1348-0421.1982.tb00254.x","article-title":"Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera","volume":"26","author":"Taguchi","year":"1982","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jmv.10450","article-title":"Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40","volume":"71","author":"Knowles","year":"2003","journal-title":"J Med Virol"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib6","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/cid\/ciu291","article-title":"Proposed clinical case definition for cytomegalovirus-immune recovery retinitis","volume":"59","author":"Ruiz-Cruz","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2042098612453849","article-title":"Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps","volume":"3","author":"Zaheer","year":"2012","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10096-013-1941-6","article-title":"Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV\/AIDS patients in the current era","volume":"33","author":"Casado","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/13550289809113482","article-title":"Progressive multifocal leukoencephalopathy in patients with HIV infection","volume":"4","author":"Berger","year":"1998","journal-title":"J Neurovirol"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib11","unstructured":"Barts and The London School of Medicine and Dentistry. Multiple Sclerosis Research. ClinicSpeak: natalizumab PML update\u2014September 2014. \u3008http:\/\/multiple-sclerosis-research.blogspot.com\/2014\/10\/clinicspeak-natalizumab-pml-update.html\u3009; 2015 [accessed 20.02.15]."},{"key":"10.1016\/j.semarthrit.2015.06.003_bib12","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","article-title":"Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies","volume":"64","author":"Molloy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib13","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib16","unstructured":"Biogen Idec Inc. Cambridge, MA; 2013 [package insert]."},{"key":"10.1016\/j.semarthrit.2015.06.003_bib17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","volume":"74","author":"Berger","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib18","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMc1214233","article-title":"JC viremia in natalizumab-treated patients with multiple sclerosis","volume":"368","author":"Major","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib19","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib20","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.beem.2013.05.011","article-title":"Heterophilic antibody interference in immunometric assays","volume":"27","author":"Bolstad","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib22","unstructured":"Stratify JCV DxSelect (enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of human antibodies to JC virus); 2013. Cypress, CA: Focus Diagnostics [package insert]."},{"key":"10.1016\/j.semarthrit.2015.06.003_bib23","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1136\/annrheumdis-2012-201638","article-title":"Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study","volume":"71","author":"Arkema","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrrheum.2014.167","article-title":"Sorting out the risks in progressive multifocal leukoencephalopathy","volume":"11","author":"Calabrese","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib25","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","article-title":"Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases","volume":"60","author":"Molloy","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib26","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","article-title":"Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis","volume":"68","author":"Clifford","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib27","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Federal Drug Administration Advisory Committee. Application number: 125476Orig1s000. Cross discipline team leader review. \u3008http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125476Orig1s000CrossR.pdf\u3009; 2014 [accessed 18.09.14]."},{"key":"10.1016\/j.semarthrit.2015.06.003_bib28","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2015.06.003_bib29","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Briefing document for the joint meeting of the Gastrointestinal Drugs Advisory Committee (GIDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRMAC); December 9, 2013. \u3008http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/GastrointestinalDrugsAdvisoryCommittee\/UCM377618.pdf\u3009; 2015 [accessed 07.01.15]."},{"key":"10.1016\/j.semarthrit.2015.06.003_bib30","article-title":"Progressive multifocal leukoencephalopathy therapy","volume":"17","author":"Clifford","year":"2015","journal-title":"J Neurovirol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215001419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215001419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T14:24:39Z","timestamp":1537539879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017215001419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0049017215001419"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.06.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}